We are a late-stage biotechnology company that promotes improved global health through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.
We have more than a decade of experience contending with some of the world’s most devastating diseases, including COVID-19, seasonal influenza, RSV, Ebola, MERS, and SARS. Hard-won lessons and significant advances illustrate that our proven technology has tremendous potential to make a substantial contribution to public health worldwide.
Our vaccine candidates are genetically engineered using three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis.
We are also developing proprietary immune-stimulating saponin-based adjuvants at Novavax AB, our wholly owned Swedish subsidiary. Matrix-M™ has been shown to enhance immune responses and has been well tolerated in multiple clinical trials.
Novavax CZ, located in Bohumil near Kostelec nad Černými lesy in the Czech Republic, is a state-of-the-art vaccine and biologics manufacturing facility dedicated to producing vaccines that improve global health. The facility currently employs approximately 250 scientists, engineers and support staff with expertise in the fields of vaccine production, biologics manufacturing, and production engineering. Novavax CZ continues to grow as we grow and expands its capabilities.
The facility became Novavax CZ after the company acquired Praha Vaccines as a strategic investment in May 2020 to dramatically expand its manufacturing capacity for production of innovative vaccines amid the global COVID-9 pandemic. Initial production at the Novavax CZ facility is focused on using Novavax’ recombinant nanoparticle technology to manufacture vaccine antigen derived from the coronavirus spike (S) protein, a key component for our COVID-19 candidate vaccine.
In the future, this facility could be used for production of other vaccines, such as our influenza candidate.
Novavax AB is located in Uppsala, Sweden. This facility is responsible for research, development and production of our saponin-based adjuvants. Our Matrix-M™ is used in multiple vaccine candidates to enhance the immune response and stimulate high levels of neutralizing antibodies.
Learn more about the global management of Novavax, Inc. at this link.
Jakub Kronovetr is the Site Director, located in Bohumil near Kostelec nad Cernymi lesy in the Central Bohemian region, with responsibility for overseeing activities of Novavax CZ. Mr. Kronovetr has been working in the Bohumil facility since 2003, holding various managerial positions when it was owned by Baxter BioScience, and named head of the production facility in 2017.
Jakub Kronovetr received his Ph.D. from Charles University in 2001 in the field of biochemistry. He spent a year with protein research at the University of Vienna. Between 1996 and 2003, he was also involved in protein research at the Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic. In 2003, Mr. Kronovetr also received RNDr. title (Doctorate in Natural Sciences) from the Faculty of Science at Charles University.
After World War I, the first National Institute of Health of the Czechoslovak Republic was established on the grounds of a former agricultural facility in Bohumil. Its goal was to develop and produce serum and vaccines as well as supervise the quality of food and pharmaceuticals. After World War II, the National Institute of Health relocated to Prague and only its serum and vaccine production facility remained in Bohumil, operating under the name of Biogena and later Sevac.
Following the Velvet Revolution, a plasma processing plant was built in Bohumil. In 2001, the facility was acquired by the American company Baxter and until 2015 produced flu vaccines using the advanced serum-free Vero cell technology for its European vaccine division. After which time the Cyrus Poonawalla Group purchased the facility from Baxter. In May 2020, the Bohumil facility was acquired by Novavax to expand the manufacturing capabilities and address the immediate need for production of a vaccine against COVID-19. Future plans include production of Novavax seasonal flu vaccine, NanoFlu™, and other emerging infectious diseases to address global health threats.